Thermal purification run on Lac Knife concentrate material produced and characterized by AETC has resulted in 99.9992 wt. % C purity – laying the foundation for the transition into the nuclear spec material purityOTTAWA, ON, June 12, 2025 /PRNewswire/ - Focus Graphite Advanced Materials Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") is pleased to announce that recent thermal purification testing completed by American Energy Technologies Company ("AETC") has successfully refined Lac K ...

Fresenius (FMS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earnings pictu ...

BAD HOMBURG, Germany, June 4, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today begins the second phase of the company's efforts to introduce high-volume hemodiafiltration (HVHDF) kidney replacement therapy across the United States. The company last week received FDA 510(k) clearance for the updated version of its new, hemodiafiltration-capable 5008X CAREsystem with additional features, a key benchmark enabling ...

Key abstract presentations showcase significant advancements in clinical care, artificial intelligence, and fluid management, demonstrating Fresenius Medical Care's commitment to improving patient outcomes. Top Abstract recognition for "Prevalence and Patterns of Intradialytic Arterial Oxygen Saturation Instability: Observations in a Large U.S. Hemodialysis Cohort," presented in the "Dialysis" category. CONVINCE trial analysis links hemodiafiltration to slower health decline and better quality of life in k ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock char ...

Core Viewpoint - Fresenius Medical Care (FMS) is set to report its first-quarter 2025 results, with expectations of revenue growth and improved earnings per share compared to the previous year [1][9]. Performance Drivers - The FME25 transformation program has delivered EUR 567 million in cumulative savings, aiding in operational efficiencies across various functions [2][12]. - Positive momentum in U.S. same-market treatment growth was noted, with a 0.5% increase in the fourth quarter of 2024, indicating successful clinic operations [3][6]. Segment Analysis - The Care Enablement segment experienced a 10% organic revenue increase and a six-fold rise in operating income, reaching a margin of 7.8% [4][7]. - The Care Delivery segment showed stabilization with slight growth in treatment volumes, although it continues to face challenges from elevated mortality rates and labor shortages [6][5]. Financial Estimates - The Zacks Consensus Estimate for revenues is $5.25 billion, reflecting a 2.3% year-over-year growth, while earnings per share are estimated at $0.43, indicating a 19.4% improvement [9][10]. Long-Term Growth Potential - FMS aims for EUR 750 million in sustainable cost savings by the end of 2025, an increase from the previous target, with significant operational improvements already achieved [12]. - The upcoming launch of the FDA-approved 5008X Hemodiafiltration system is expected to enhance patient outcomes and drive growth [13]. Value-Based Care Strategy - The company is expanding its value-based care model through InterWell Health, managing over $11 billion in medical costs, with expectations of breakeven performance in 2025 [14].

One stock that might be an intriguing choice for investors right now is Fresenius Medical Care AG (FMS) . This is because this security in the Medical - Instruments space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in ...

Core Viewpoint - Fresenius Medical Care AG & Co. (FMS) is positioned for growth through strategic acquisitions and partnerships, despite facing a challenging regulatory environment [1][8]. Company Overview - FMS has a market capitalization of $15.06 billion and is a leading provider of dialysis products and services for chronic kidney failure patients [2]. - The company's earnings are expected to improve by 11.9% over the next five years, with a history of beating earnings estimates in the last four quarters, averaging a surprise of 15.67% [2]. Growth Factors - **Strategic Acquisitions & Partnerships**: FMS has acquired NxStage Medical for $30 per share, anticipating earnings accretion within three years and annual pre-tax savings of $80 million to $100 million. The 2025 growth strategy includes merging Fresenius Health Partners, InterWell Health, and Cricket Health to manage 270,000 kidney disease patients with $11 billion in medical costs. Additionally, FMS has expanded its home dialysis market through a distribution deal with JMS Co. Ltd. in Japan and extended agreements with DaVita and Aetna [3]. - **Strong Global Foothold**: FMS has a robust presence in North America, Europe, Asia Pacific, and Latin America, achieving organic growth and strategic acquisitions. The company entered the dialysis market in Israel and acquired an 85% stake in Sandor Nephro Services in India, while also focusing on public-private partnerships to explore new markets [4]. - **Strong Q4 Results**: FMS reported strong Q4 results, surpassing earnings and revenue estimates, driven by pricing momentum in the Care Enablement segment [5]. Financial Performance - The FME25 transformation program achieved EUR 221 million in sustainable savings in 2024, exceeding its target, with total accumulated savings reaching EUR 567 million. FMS has raised its 2025 savings target to EUR 750 million, despite expected one-time costs of EUR 700-750 million [7]. - The Zacks Consensus Estimate for 2025 revenues is $21.08 billion, indicating flat year-over-year growth, while the consensus for earnings is $2.11 per share, reflecting a growth of 27.1% from the previous year. Earnings estimates have improved by 19 cents in the past 90 days [9].

The U.S. stock market experienced a strong rebound earlier this week, as the Dow Jones Industrial Average gained 500 points, and the S&P 500 and the Nasdaq Composite rose 1.5% and 1.8%, respectively, on March 24. This rally has, to some extent, rekindled investor interest in equities, which had been under pressure amid concerns about recession and policy-induced trade disruptions.The latest gains stem from renewed investor optimism following indications that President Trump's upcoming set of tariffs may be ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are t ...